Oslo, Norway, 11 March 2026: The Board of Directors has today resolved to grant
CEO Øystein Soug 31,884 share options in the Company under the Company's long
term incentive program, each with a strike price of NOK 42.98, equal to the
volume weighted average share price the last day before the grant. See the
attached form. Following the grant of the 31,884 share options referred to
above, Øystein Soug hold 10,576 shares and 92,949 options in the Company.

Each option, when exercised, will give the right to acquire one share in the
Company. The options are granted without consideration. No Options shall vest
during the first 12 months following the date of the Grant Letter, 13/48 of the
Options shall vest in the 13th month, and the remaining Options shall thereafter
vest in equal monthly instalments of 1/48 (as long as the option holder is still
employed). Options that have not been exercised will lapse 7 years after the
date of grant.

The board considers an option program as an important element in attracting and
retaining employees to foster long-term success. The board considers the option
program terms and allocation to be at the market for comparable peers.

PDMR notice (https://mb.cision.com/Public/15728/4320109/a217a317d05bac68.pdf)

This information is subject to the disclosure requirements pursuant to
Regulation (EU) 596/2014 (MAR) Article 19 and Section 5-12 of the Norwegian
Securities Trading Act.

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com (soug@oncoinvent.com)

About Oncoinvent

Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation
therapy that leverages the unique anatomy of the abdominal cavity to destroy
residual micrometastases using a single, highly localized dose of alpha
radiation. The initial clinical focus is treatment of ovarian and colorectal
cancer patients after surgical removal of the primary tumor and visible
metastases in the peritoneum, the thin membrane lining the abdominal cavity and
covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the
peritoneal cavity, keeping patients disease-free for longer than the current
standard of care and thereby also impacting overall survival. It is broadly
applicable to any cancer that spreads to the peritoneum, e.g. ovarian,
colorectal, and gastric cancers. Radspherin stands out for its simplicity,
excellent safety profile, and seamless integration into existing surgical
workflows. Oncoinvent's product is easy to use, avoids systemic delivery and
significant toxicity. It is also differentiated in being simple to manufacture,
scalable, and supply de-risked.

Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers,
are highly promising, showing an excellent safety profile and meaningful signals
of efficacy. Interim data from an ongoing, randomized, controlled phase 2
ovarian cancer trial is expected in 2026. With cost-effective manufacturing,
blockbuster potential, active pharma partnership momentum, plus strong
endorsements from leading experts, Oncoinvent is built for scale and commercial
success, and is set to become the new standard for post-surgical cancer care.
The Company was founded by the originators of Algeta and Xofigo (acquired by
Bayer).